ArticleMolecular medicine (Cambridge, Mass.)2021

The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

Xilin Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.